<![CDATA[Merck 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=48198>Wed, 29 Apr 2026 18:13:13 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor]]>https://www.newswire.co.kr/newsRead.php?no=1026821Tue, 13 Jan 2026 09:02:34 +0900<![CDATA[Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor]]>https://www.newswire.co.kr/newsRead.php?no=1025903Tue, 23 Dec 2025 09:19:27 +0900<![CDATA[Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis]]>https://www.newswire.co.kr/newsRead.php?no=1023820Tue, 25 Nov 2025 09:40:27 +0900<![CDATA[Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT]]>https://www.newswire.co.kr/newsRead.php?no=1020898Sun, 19 Oct 2025 16:02:01 +0900<![CDATA[Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025]]>https://www.newswire.co.kr/newsRead.php?no=1019028Thu, 18 Sep 2025 13:55:00 +0900<![CDATA[Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025]]>https://www.newswire.co.kr/newsRead.php?no=1013017Fri, 13 Jun 2025 08:53:06 +0900<![CDATA[China’s Center for Drug Evaluation Accepts Merck’s Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor]]>https://www.newswire.co.kr/newsRead.php?no=1012803Tue, 10 Jun 2025 14:10:00 +0900